Skip to content
Screener

EyePoint, Inc. EYPT Q3 2026 earnings

Reported November 12, 2026 · Before market open

Revenue$756.0KBeat by $524.8K
EPS-$1.07Miss by $0.14
Revenue estimate$231.2K
EPS estimate-$0.93
“Our conviction in the DME program is further grounded in the positive Phase 2 VERONA trial results, the multi-MOA activity for DURAVYU addressing the distinct biology of DME driven by both inflammatory pathways as well as vascular endothelial growth factor (VEGF), the substantial clinical experience established with DURAVYU, and the opportunity to evaluate the program in two fully enrolled, well-controlled pivotal trials within a year.”
Jay S. Duker

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$756.0K-21.7%
Operating income-$96.9M-56.2%
Net income-$95.6M-60.1%
EPS (diluted)-$1.07-25.9%

Balance sheet

See full
Cash & equivalents$83.2M+11.6%
Total debt$21.8M-6.5%
Total equity$108.5M-45.8%
Total assets$166.1M-34.0%

Cash flow

See full
Operating cash flow-$86.8M-46.3%
CapEx$1.2M+51.1%
Free cash flow-$88.0M-46.3%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$31.2M-96.7%
Enterprise value-$30.25M-103%
P/S12.1×-10.1×

Profitability

See full
Operating margin-13,642%-14,200pp
Net margin-13,281.2%-13,806pp
FCF margin-11,599.4%-12,152pp

Returns & leverage

See full
Return on equity-221.9%-1,078pp
Debt / equity0.2×+0.1×
Current ratio3.3×-3.9×

Segments

By product

See full
Royalty$200.0K-14.5%
License And Collaboration Agreement$49.0K-67.3%
Product Rights Agreement-—

FAQ

When did EyePoint, Inc. report Q3 2026 earnings?
EyePoint, Inc. (EYPT) reported Q3 2026 earnings on November 12, 2026 before market open.
What were EyePoint, Inc.'s Q3 2026 revenue and EPS?
EyePoint, Inc. reported revenue of $756.0K and eps of $-1.07 for Q3 2026.
Did EyePoint, Inc. beat estimates in Q3 2026?
Revenue beat the consensus estimate of $231.2K by $524.8K. EPS missed the consensus estimate of $-0.93 by $0.14.
How did EyePoint, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 21.7% from $966.0K a year earlier and eps declined 25.9% from $-0.85.
Where can I find EyePoint, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-456889) and the 10-Q periodic report (0001193125-26-458319) directly on SEC EDGAR. The filing index links above go to sec.gov.